27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
The FDA has approved Alnylam Pharmaceuticals Inc's (NASDAQ:ALNY) Leqvio (inclisiran) to lower low-density lipoprotein cholesterol (LDL-C).
- Leqvio is indicated in the U.S. as an adjunct to diet and maximally tolerated statin therapy to treat clinical atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia, requiring additional LDL-C lowering.
- Related: Read Why Analysts Are Going Bullish On This Large-Cap Pharma Stock.
- As of January 2020, Novartis AG (NYSE:NVS) obtained global rights to develop, manufacture, and commercialize inclisiran under a license and collaboration agreement.
- Novartis AG continues developing inclisiran and commercializing Leqvio worldwide, with Alnylam eligible to receive tiered royalties between 10 % - 20% on global sales.
- Leqvio is the fourth Alnylam-discovered medicine using its RNAi therapeutic platform to be approved to date.
- The Leqvio approval marks the first U.S. approval of an RNAi therapeutic indicated to treat a major risk factor for a highly prevalent disease.
- Related content: Benzinga's Full FDA Calendar.
- Price Action: ALNY shares closed at $187.38 on Wednesday, and NVS stock is up 0.50% at $86.74 during the premarket session on the last check Thursday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!